ONCAlert | 2018 ASCO Annual Meeting

Ongoing Trial of Abemaciclib and Pembrolizumab in HR+/HER2-Negative Breast Cancer

Maura N. Dickler, MD
Published Online: 4:09 PM, Fri December 9, 2016

Maura N. Dickler, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an ongoing clinical trial of the CDK4/6 inhibitor abemaciclib combined with the PD-L1 inhibitor pembrolizumab (Keytruda) for patients with hormone receptor (HR)-positive, HER2-negative breast cancer. She also sheds light on abemaciclib's unique mechanism of action.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.